Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk

Dow Jones

Jan 30

2347 GMT - Imaging-tech provider Pro Medicus has underperformed Australia's benchmark S&P/ASX 200 index so far this year. For investors, that offers an attractive setup ahead of its 1H result next month, MS says. It points to record contract implementations by Pro Medicus and stable demand. At the same time, estimates are conservative and AI concerns are overstated, analyst Chris Boulus says. MS forecasts 1H revenue growth of 36% on year and an Ebitda margin of 77%. MS retains an overweight call and A$350.00/share price target on Pro Medicus, which is down 0.4% at A$181.00. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

January 29, 2026 18:47 ET (23:47 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2607050531"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607050531\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607050531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 07:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607050531","market":"fut","top_or_hot":-1,"title":"Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2347 GMT - Imaging-tech provider <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> has underperformed Australia's benchmark S&amp;P/ASX 200 index so far this year. For investors, that offers an attractive setup ahead of its 1H result next month, MS says. It points to record contract implementations by <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> and stable demand. At the same time, estimates are conservative and AI concerns are overstated, analyst Chris Boulus says. MS forecasts 1H revenue growth of 36% on year and an Ebitda margin of 77%. MS retains an overweight call and A$350.00/share price target on <a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a>, which is down 0.4% at A$181.00. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 18:47 ET (23:47 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pro Medicus Looks Attractive Ahead of 1H Result -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPro Medicus Looks Attractive Ahead of 1H Result -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-30 07:47</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2347 GMT - Imaging-tech provider <a href=\"https://laohu8.com/S/PMCUF\">Pro Medicus</a> has underperformed Australia's benchmark S&amp;P/ASX 200 index so far this year. For investors, that offers an attractive setup ahead of its 1H result next month, MS says. It points to record contract implementations by <a href=\"https://laohu8.com/S/PMDIY\">Pro Medicus</a> and stable demand. At the same time, estimates are conservative and AI concerns are overstated, analyst Chris Boulus says. MS forecasts 1H revenue growth of 36% on year and an Ebitda margin of 77%. MS retains an overweight call and A$350.00/share price target on <a href=\"https://laohu8.com/S/PME.AU\">Pro Medicus</a>, which is down 0.4% at A$181.00. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 29, 2026 18:47 ET (23:47 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7094","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2607050531","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607050531","pubTimestamp":1769730420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2347 GMT - Imaging-tech provider Pro Medicus has underperformed Australia's benchmark S&P/ASX 200 index so far this year. For investors, that offers an attractive setup ahead of its 1H result next month, MS says. It points to record contract implementations by Pro Medicus and stable demand. At the same time, estimates are conservative and AI concerns are overstated, analyst Chris Boulus says. MS forecasts 1H revenue growth of 36% on year and an Ebitda margin of 77%. MS retains an overweight call and A$350.00/share price target on Pro Medicus, which is down 0.4% at A$181.00. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7094":"医疗保健技术","PME.AU":"PRO MEDICUS LTD"},"translate_title":"Pro Medicus在上半年业绩公布前看起来很有吸引力——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PME.AU":0.9},"content_text":"2347 GMT - Imaging-tech provider Pro Medicus has underperformed Australia's benchmark S&P/ASX 200 index so far this year. For investors, that offers an attractive setup ahead of its 1H result next month, MS says. It points to record contract implementations by Pro Medicus and stable demand. At the same time, estimates are conservative and AI concerns are overstated, analyst Chris Boulus says. MS forecasts 1H revenue growth of 36% on year and an Ebitda margin of 77%. MS retains an overweight call and A$350.00/share price target on Pro Medicus, which is down 0.4% at A$181.00. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 18:47 ET (23:47 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}